Mechanisms of resistance to trastuzumab as neoadjuvant therapy in women with HER2-overexpressing operable breast cancer.

被引：0
|
作者：
Jinno, Hiromitsu
Sato, Tomomi
Hayashida, Tetsu
Takahashi, Maiko
Hirose, Shigemichi
Kitagawa, Yuko
机构：
[1] Keio Univ, Sch Med, Tokyo, Japan
[2] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11060
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Clara Natoli
    Patrizia Vici
    Isabella Sperduti
    Antonino Grassadonia
    Giancarlo Bisagni
    Nicola Tinari
    Andrea Michelotti
    Germano Zampa
    Stefania Gori
    Luca Moscetti
    Michele De Tursi
    Michele Panebianco
    Maria Mauri
    Ilaria Ferrarini
    Laura Pizzuti
    Corrado Ficorella
    Riccardo Samaritani
    Lucia Mentuccia
    Stefano Iacobelli
    Teresa Gamucci
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1229 - 1240
  • [2] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Natoli, Clara
    Vici, Patrizia
    Sperduti, Isabella
    Grassadonia, Antonino
    Bisagni, Giancarlo
    Tinari, Nicola
    Michelotti, Andrea
    Zampa, Germano
    Gori, Stefania
    Moscetti, Luca
    De Tursi, Michele
    Panebianco, Michele
    Mauri, Maria
    Ferrarini, Ilaria
    Pizzuti, Laura
    Ficorella, Corrado
    Samaritani, Riccardo
    Mentuccia, Lucia
    Iacobelli, Stefano
    Gamucci, Teresa
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (07) : 1229 - 1240
  • [3] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    CANCER RESEARCH, 2012, 72
  • [4] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models
    Albrecht, Huguette
    IMMUNOTHERAPY, 2010, 2 (06) : 795 - 798
  • [6] Effects of trastuzumab and paclitaxel in HER2-overexpressing breast cancer
    Li, Songhua
    Higuchi, Hideo
    Ohuchi, Noriaki
    FUTURE MEDICAL ENGINEERING BASED ON BIONANOTECHNOLOGY, PROCEEDINGS, 2006, : 395 - +
  • [7] Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
    Valabrega, G.
    Montemurro, F.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 977 - 984
  • [8] Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    Shattuck, David L.
    Miller, Jamie K.
    Carraway, Kermit L., III
    Sweeney, Colleen
    CANCER RESEARCH, 2008, 68 (05) : 1471 - 1477
  • [9] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    Burstein, HJ
    Kuter, I
    Campos, SM
    Gelman, RS
    Tribou, L
    Parker, LM
    Manola, J
    Younger, J
    Matulonis, U
    Bunnell, CA
    Partridge, AH
    Richardson, PG
    Clarke, K
    Shulman, LN
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2722 - 2730
  • [10] Role of HSP27 in trastuzumab resistance in HER2-overexpressing breast cancer
    Hwang, S-Y.
    Choi, S-K.
    Na, Y.
    Lee, Y-S.
    Kwon, Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 24 - 24
12345